Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of Fixed Dose Combination RHB-104 as Add-On Therapy to Interferon Beta-1a in Patients Treated for Relapsing Remitting Multiple Sclerosis

Next Previous
X
Search
Trial Profile

A Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of Fixed Dose Combination RHB-104 as Add-On Therapy to Interferon Beta-1a in Patients Treated for Relapsing Remitting Multiple Sclerosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clarithromycin/clofazimine/rifabutin (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms CEASE-MS
  • Sponsors RedHill Biopharma

    • Most Recent Events

    • 12 Dec 2016 Top-line final results published in the RedHill Biopharma media release.
    • 01 Aug 2016 Interim results published in a RedHill Biopharma media release.
    • 01 Aug 2016 According to a RedHill Biopharma media release, top-line results from this trial are expected in the fourth quarter of 2016.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top